- Trials with a EudraCT protocol (382)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
382 result(s) found for: Birth order.
Displaying page 5 of 20.
EudraCT Number: 2020-002448-21 | Sponsor Protocol Number: ACTIVATEII | Start Date*: 2020-05-26 | ||||||||||||||||
Sponsor Name:Hellenic Institute for the Study of Sepsis | ||||||||||||||||||
Full Title: A RANDOMIZED CLINICAL TRIAL FOR ENHANCED TRAINED IMMUNE RESPONSES THROUGH BACILLUS CALMETTE-GUÉRIN VACCINATION TO PREVENT INFECTIONS ΒΥ COVID-19: THE ACTIVATE II TRIAL | ||||||||||||||||||
Medical condition: Prevention of COVID-19 infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002292-18 | Sponsor Protocol Number: 7569 | Start Date*: 2019-05-24 |
Sponsor Name:University Hospital of Montpellier | ||
Full Title: CT air-trapping characterization for the early identification of Benralizumab responders among eosinophilic asthma patients | ||
Medical condition: The study population corresponds to severe eosinophilic asthma patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-004814-41 | Sponsor Protocol Number: M06-806 | Start Date*: 2007-08-07 | |||||||||||
Sponsor Name:Abbott GmbH & Co. KG | |||||||||||||
Full Title: A Multicenter, Double-Blind Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects with Moderate to Severe Crohn's Di... | |||||||||||||
Medical condition: Moderate to Severe Crohn's Disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) CZ (Completed) BE (Completed) NL (Completed) GB (Completed) IT (Prematurely Ended) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004158-17 | Sponsor Protocol Number: GELTAMO-IMCL-2015 | Start Date*: 2016-02-15 | |||||||||||
Sponsor Name:GELTAMO (Grupo Cooperativo Español de Llinfoma/Trasplante Autólogo de Médula Ósea) | |||||||||||||
Full Title: Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab in patients with indolent clinical forms of Mantle Cell Lymphoma. | |||||||||||||
Medical condition: Mantle Cell Lyphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004380-44 | Sponsor Protocol Number: 112899 | Start Date*: 2015-05-20 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A Phase II, open-label, randomised controlled study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ candidate tuberculosis (TB) vaccine (M72/AS01E) when administered i... | ||
Medical condition: Healthy volunteers (evaluation of safety and reactogenicity of TB vaccine when administered in healthy infants) | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2015-005228-24 | Sponsor Protocol Number: 402-C-327 | Start Date*: 2016-06-10 | |||||||||||
Sponsor Name:Pacira Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Brachial Plexus Block with EXPAREL for Postsurgical Analgesia in Subjects ... | |||||||||||||
Medical condition: Total Shoulder Arthroplasty or Rotator Cuff Repair | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004892-21 | Sponsor Protocol Number: IP-004 | Start Date*: 2008-04-08 |
Sponsor Name:IMMUPHARMA SA | ||
Full Title: Estudio Fase IIb, Multicéntrico, Aleatorizado, Doble-Ciego, Controlado con Placebo de Búsqueda de dosis, para Evaluar Eficacia, Seguridad y Tolerabilidad de Dos Dosis Subcutáneas de IPP-201101 Más ... | ||
Medical condition: Lupus Eritematoso Sistémico (LES) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) BG (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001671-21 | Sponsor Protocol Number: KRT-232-101 | Start Date*: 2018-10-03 | |||||||||||||||||||||
Sponsor Name:Kartos Therapeutics, Inc. | |||||||||||||||||||||||
Full Title: An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post–ET-MF) Who Have Failed P... | |||||||||||||||||||||||
Medical condition: Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF(Post–ET-MF) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) CZ (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) ES (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) LT (Trial now transitioned) IT (Trial now transitioned) PT (Trial now transitioned) HR (Trial now transitioned) GR (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002449-31 | Sponsor Protocol Number: ZP4207-16137 | Start Date*: 2018-02-16 | |||||||||||
Sponsor Name:Zealand Pharma A/S | |||||||||||||
Full Title: A phase 3, randomized, double-blind, parallel trial to confirm the clinical efficacy and safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 1 diabetes mellitus (T1... | |||||||||||||
Medical condition: Type 1 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003666-41 | Sponsor Protocol Number: MEC2020-0078 | Start Date*: 2020-04-21 | |||||||||||
Sponsor Name:Erasmus MC University Medical Center | |||||||||||||
Full Title: Doxapram versus placebo in preterm newborns: an international double blinded multicenter randomized controlled trial. | |||||||||||||
Medical condition: Preterm infants are at high risk of respiratory failure due to immaturity of the respiratory system. Respiratory failure is caused by a comprised lung function and impaired control of breathing. Co... | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016374-32 | Sponsor Protocol Number: MK-0462-082 | Start Date*: 2010-02-15 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Worldwide, Randomized, Double Blind, Placebo-Controlled, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Rizatriptan for the Acute Treatment of Migraine in Children and Adole... | |||||||||||||
Medical condition: Acute treatment of migraine, with or without aura, in children and adolescents, ages 6 to 17 years, who do not have a satisfactory response to prior treatment with nonsteroidal anti-inflammatory dr... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) FI (Completed) BE (Completed) ES (Completed) EE (Completed) LV (Completed) SE (Completed) FR (Completed) DK (Completed) GB (Completed) IT (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014453-32 | Sponsor Protocol Number: BPS-MR-PAH-204,Amdt2US,BEL,RO | Start Date*: 2010-01-11 | |||||||||||
Sponsor Name:Lung LLC | |||||||||||||
Full Title: An open-label extension of BPS-MR-PAH-203 in pulmonary arterial hypertension (PAH) patients | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) IE (Completed) DE (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002731-32 | Sponsor Protocol Number: D/P3/21/7 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Diamyd Medical AB | |||||||||||||
Full Title: A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Diamyd® to Preserve Endogenous Beta Cell Function in Adolescents and Adults with... | |||||||||||||
Medical condition: Type 1 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) DE (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned) EE (Trial now transitioned) HU (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001548-30 | Sponsor Protocol Number: AB0602 | Start Date*: 2006-10-16 | |||||||||||
Sponsor Name:Artu Biologicals Europe B.V. | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled, multi-centre, multi-national Phase II / III study to assess the efficacy and safety of three different dose regimens of Oralgen® Grass Pollen in pati... | |||||||||||||
Medical condition: Grass pollen-related rhinoconjunctivitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) SK (Completed) LT (Completed) NL (Completed) HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002309-30 | Sponsor Protocol Number: P04230 | Start Date*: 2007-06-18 | |||||||||||
Sponsor Name:Schering-Plough Research Institute, a division of Schering Corporation | |||||||||||||
Full Title: A Randomized Placebo-Controlled Efficacy and Safety Study of 1-Year Duration with High and Medium Dose Inhaled Mometasone Furoate/Formoterol Combination Formulation Compared With Formoterol and Hig... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) NL (Completed) HU (Completed) SK (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004010-18 | Sponsor Protocol Number: M-41008-47 | Start Date*: 2019-05-22 | |||||||||||
Sponsor Name:Almirall Ltd | |||||||||||||
Full Title: An Open Label, Multi-Center, 24 Week, Exploratory Study to Assess the Efficacy and Safety of Skilarence® (Dimethyl Fumarate) in Patients with Moderate Plaque Psoriasis | |||||||||||||
Medical condition: Moderate Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022759-42 | Sponsor Protocol Number: CNTO1275CRD3002 | Start Date*: 2011-08-29 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severe... | |||||||||||||
Medical condition: Moderately to severely active Crohn's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) BE (Completed) ES (Completed) NL (Completed) HU (Completed) IS (Completed) BG (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014986-22 | Sponsor Protocol Number: NC25113 | Start Date*: 2009-11-24 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A randomized double blind, placebo-controlled clinical trial to assess the effects of taspoglutide (RO5073031) on cardiovascular outcomes in subjects with inadequately controlled type 2 diabetes an... | |||||||||||||
Medical condition: Patients with Type 2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Prematurely Ended) HU (Prematurely Ended) EE (Prematurely Ended) CZ (Prematurely Ended) DE (Completed) SK (Prematurely Ended) ES (Completed) DK (Completed) BG (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000674-73 | Sponsor Protocol Number: LJP 394-90-14 | Start Date*: 2006-08-11 | |||||||||||
Sponsor Name:La Jolla Pharmaceutical Company | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, THREE-ARM, PARALLEL-GROUP, MULTICENTER, MULTINATIONAL SAFETY AND EFFICACY TRIAL OF 300 MG AND 900 MG OF ABETIMUS SODIUM IN SYSTEMIC LUPUS ERYTHEMATOS... | |||||||||||||
Medical condition: Systemic lupus erythematosus patients with a history of renal disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) SK (Completed) PT (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) ES (Ongoing) IT (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003987-29 | Sponsor Protocol Number: APD334-303 | Start Date*: 2019-06-25 | ||||||||||||||||
Sponsor Name:Arena Pharmaceuticals Inc. a wholly owned subsidiary of Pfizer Inc. | ||||||||||||||||||
Full Title: An Open-Label Extension Study of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis | ||||||||||||||||||
Medical condition: Ulcerative Colitis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SK (Trial now transitioned) BE (Trial now transitioned) NL (Ongoing) CZ (Trial now transitioned) EE (Ongoing) FR (Trial now transitioned) LV (Completed) HU (Trial now transitioned) DE (Trial now transitioned) DK (Completed) AT (Completed) BG (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) LT (Trial now transitioned) ES (Ongoing) HR (Completed) IT (Trial now transitioned) RO (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
